当前位置: 首页 >> 检索结果
共有 16360 条符合本次的查询结果, 用时 1.7814556 秒

201. Drug development in IBD: from novel target identification to early clinical trials.

作者: Silvio Danese.;Claudio Fiocchi.;Julián Panés.
来源: Gut. 2016年65卷8期1233-9页

202. Experimental infection of rabbits with genotype 3 hepatitis E virus produced both chronicity and kidney injury.

作者: Lin Wang.;Junke Xia.;Ling Wang.;Youchun Wang.
来源: Gut. 2017年66卷3期561-562页

203. Transition from childhood to adulthood in coeliac disease: the Prague consensus report.

作者: Jonas F Ludvigsson.;Lars Agreus.;Carolina Ciacci.;Sheila E Crowe.;Marilyn G Geller.;Peter H R Green.;Ivor Hill.;A Pali Hungin.;Sibylle Koletzko.;Tunde Koltai.;Knut E A Lundin.;M Luisa Mearin.;Joseph A Murray.;Norelle Reilly.;Marjorie M Walker.;David S Sanders.;Raanan Shamir.;Riccardo Troncone.;Steffen Husby.
来源: Gut. 2016年65卷8期1242-51页
The process of transition from childhood to adulthood is characterised by physical, mental and psychosocial development. Data on the transition and transfer of care in adolescents/young adults with coeliac disease (CD) are scarce. In this paper, 17 physicians from 10 countries (Sweden, Italy, the USA, Germany, Norway, the Netherlands, Australia, Britain, Israel and Denmark) and two representatives from patient organisations (Association of European Coeliac Societies and the US Celiac Disease Foundation) examined the literature on transition from childhood to adulthood in CD. Medline (Ovid) and EMBASE were searched between 1900 and September 2015. Evidence in retrieved reports was evaluated using the Grading of Recommendation Assessment, Development and Evaluation method. The current consensus report aims to help healthcare personnel manage CD in the adolescent and young adult and provide optimal care and transition into adult healthcare for patients with this disease. In adolescence, patients with CD should gradually assume exclusive responsibility for their care, although parental support is still important. Dietary adherence and consequences of non-adherence should be discussed during transition. In most adolescents and young adults, routine small intestinal biopsy is not needed to reconfirm a childhood diagnosis of CD based on European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) or North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) criteria, but a biopsy may be considered where paediatric diagnostic criteria have not been fulfilled, such as, in a patient without biopsy at diagnosis, additional serology (endomysium antibody) has not been performed to confirm 10-fold positivity of tissue transglutaminase antibodies or when a no biopsy strategy has been adopted in an asymptomatic child.

204. Lymphotoxin β receptor signalling executes Helicobacter pylori-driven gastric inflammation in a T4SS-dependent manner.

作者: Raquel Mejías-Luque.;Jessica Zöller.;Florian Anderl.;Elena Loew-Gil.;Michael Vieth.;Thure Adler.;Daniela B Engler.;Sabine Urban.;Jeffrey L Browning.;Anne Müller.;Markus Gerhard.;Mathias Heikenwalder.
来源: Gut. 2017年66卷8期1369-1381页
Lymphotoxin β receptor (LTβR) signalling has been implicated in inflammation-associated tumour development in different tissues. We have analysed the role of LTβR and alternative NF-κB signalling in Helicobacter pylori-mediated gastric inflammation and pathology.

205. Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis.

作者: Alyssa Parian.;Berkeley Limketkai.;Joyce Koh.;Steven R Brant.;Alain Bitton.;Judy H Cho.;Richard H Duerr.;Dermot P McGovern.;Deborah D Proctor.;Miguel D Regueiro.;John D Rioux.;Phil Schumm.;Kent D Taylor.;Mark S Silverberg.;A Hillary Steinhart.;Ruben Hernaez.;Mark Lazarev.
来源: Gut. 2017年66卷8期1390-1397页
Early appendectomy is inversely associated with the development of UC. However, the impact of appendectomy on the clinical course of UC is controversial, generally favouring a milder disease course. We aim to describe the effect appendectomy has on the disease course of UC with focus on the timing of appendectomy in relation to UC diagnosis.

206. Author response to letter: colonic stenting in patients on P2Y12 receptor antagonists and direct oral anticoagulants-are current BSG/ESGE guidelines practical?

作者: Andrew Veitch.;Jean-Marc Dumonceau.
来源: Gut. 2017年66卷3期560-561页

207. Stool frequency is associated with gut microbiota composition.

作者: Fatemeh Hadizadeh.;Susanna Walter.;Meriem Belheouane.;Ferdinando Bonfiglio.;Femke-Anouska Heinsen.;Anna Andreasson.;Lars Agreus.;Lars Engstrand.;John F Baines.;Joseph Rafter.;Andre Franke.;Mauro D'Amato.
来源: Gut. 2017年66卷3期559-560页

208. Reduced risk of UC in families affected by appendicitis: a Danish national cohort study.

作者: Nynne Nyboe Andersen.;Sanne Gørtz.;Morten Frisch.;Tine Jess.
来源: Gut. 2017年66卷8期1398-1402页
The possible aetiological link between appendicitis and UC remains unclear. In order to investigate the hereditary component of the association, we studied the risk of UC in family members of individuals with appendicitis.

209. The gut-adherent microbiota of PSC-IBD is distinct to that of IBD.

作者: Mohammed Nabil Quraishi.;Martin Sergeant.;Gemma Kay.;Tariq Iqbal.;Jacqueline Chan.;Chrystala Constantinidou.;Palak Trivedi.;James Ferguson.;David H Adams.;Mark Pallen.;Gideon M Hirschfield.
来源: Gut. 2017年66卷2期386-388页

210. Barriers against split-dose bowel preparation for colonoscopy.

作者: F Radaelli.;S Paggi.;A Repici.;G Gullotti.;P Cesaro.;G Rotondano.;L Cugia.;C Trovato.;C Spada.;L Fuccio.;P Occhipinti.;F Pace.;C Fabbri.;A Buda.;G Manes.;G Feliciangeli.;M Manno.;L Barresi.;A Anderloni.;P Dulbecco.;F Rogai.;A Amato.;C Senore.;C Hassan.
来源: Gut. 2017年66卷8期1428-1433页
Although split regimen is associated with higher adenoma detection and is recommended for elective colonoscopy, its adoption remains suboptimal. The identification of patient-related barriers may improve its implementation. Our aim was to assess patients' attitude towards split regimen and patient-related factors associated with its uptake.

211. Comparing CT colonography and flexible sigmoidoscopy: a randomised trial within a population-based screening programme.

作者: Daniele Regge.;Gabriella Iussich.;Nereo Segnan.;Loredana Correale.;Cesare Hassan.;Arrigo Arrigoni.;Roberto Asnaghi.;Piero Bestagini.;Gianmarco Bulighin.;Maria Carla Cassinis.;Andrea Ederle.;Andrea Ferraris.;Giovanni Galatola.;Teresa Gallo.;Giovanni Gandini.;Licia Garretti.;Maria Cristina Martina.;Daniela Molinar.;Stefania Montemezzi.;Lia Morra.;Massimiliano Motton.;Pietro Occhipinti.;Lucia Pinali.;Gian Alberto Soardi.;Carlo Senore.
来源: Gut. 2017年66卷8期1434-1440页
The role of CT colonography (CTC) as a colorectal cancer (CRC) screening test is uncertain. The aim of our trial was to compare participation and detection rate (DR) with sigmoidoscopy (flexible sigmoidoscopy (FS)) and CTC in a screening setting.

212. Protease inhibition as new therapeutic strategy for GI diseases.

作者: Nathalie Vergnolle.
来源: Gut. 2016年65卷7期1215-24页
The GI tract is the most exposed organ to proteases, both in physiological and pathophysiological conditions. For digestive purposes, the lumen of the upper GI tract contains large amounts of pancreatic proteases, but studies have also demonstrated increased proteolytic activity into mucosal tissues (both in the upper and lower GI tract), associated with pathological conditions. This review aims at outlining the evidences for dysregulated proteolytic homeostasis in GI diseases and the pathogenic mechanisms of increased proteolytic activity. The therapeutic potential of protease inhibition in GI diseases is discussed, with a particular focus on IBDs, functional GI disorders and colorectal cancer.

213. Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model.

作者: Nick Scott.;Emma S McBryde.;Alexander Thompson.;Joseph S Doyle.;Margaret E Hellard.
来源: Gut. 2017年66卷8期1507-1515页
The WHO's draft HCV elimination targets propose an 80% reduction in incidence and a 65% reduction in HCV-related deaths by 2030. We estimate the treatment scale-up required and cost-effectiveness of reaching these targets among injecting drug use (IDU)-acquired infections using Australian disease estimates.

214. Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer.

作者: Ujjwal M Mahajan.;Steffen Teller.;Matthias Sendler.;Raghavendra Palankar.;Cindy van den Brandt.;Theresa Schwaiger.;Jens-Peter Kühn.;Silvia Ribback.;Gunnar Glöckl.;Matthias Evert.;Werner Weitschies.;Norbert Hosten.;Frank Dombrowski.;Mihaela Delcea.;Frank-Ulrich Weiss.;Markus M Lerch.;Julia Mayerle.
来源: Gut. 2016年65卷11期1838-1849页
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies and is projected to be the second leading cause of cancer-related death by 2030. Despite extensive knowledge and insights into biological properties and genetic aberrations of PDAC, therapeutic options remain temporary and ineffective. One plausible explanation for the futile response to therapy is an insufficient and non-specific delivery of anticancer drugs to the tumour site.

215. Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation.

作者: Delia Blaya.;Mar Coll.;Daniel Rodrigo-Torres.;Maria Vila-Casadesús.;José Altamirano.;Marta Llopis.;Isabel Graupera.;Luis Perea.;Beatriz Aguilar-Bravo.;Alba Díaz.;Jesus M Banales.;Joan Clària.;Juan José Lozano.;Ramon Bataller.;Juan Caballería.;Pere Ginès.;Pau Sancho-Bru.
来源: Gut. 2016年65卷9期1535-45页
MicroRNAs (miRNAs) are well-known regulators of disease pathogenesis and have great potential as biomarkers and therapeutic targets. We aimed at profiling miRNAs in alcoholic hepatitis (AH) and identifying miRNAs potentially involved in liver injury.

216. MAPping the Wnt pathway to hepatocellular carcinoma recurrence.

作者: Béatrice Benoit.;Christian Poüs.
来源: Gut. 2016年65卷9期1397-400页

217. Efficacy of vonoprazan-based second-line Helicobacter pylori eradication therapy in patients for whom vonoprazan-based first-line treatment failed.

作者: Yasumi Katayama.;Kouji Toyoda.;Yuumi Kusano.;Toshikuni Suda.;Shogo Adachi.;Itsuo Terauchi.;Shigeki Oka.;Morio Takahashi.;Masaya Tamano.
来源: Gut. 2017年66卷4期752-753页

218. Hiatus hernia in healthy volunteers is associated with intrasphincteric reflux and cardiac mucosal lengthening without traditional reflux.

作者: Elaine V Robertson.;Mohammad H Derakhshan.;Angela A Wirz.;David R Mitchell.;James J Going.;Andrew W Kelman.;Stuart A Ballantyne.;Kenneth E L McColl.
来源: Gut. 2017年66卷7期1208-1215页
Hiatus hernia (HH) is a key mediator of gastro-oesophageal reflux disease but little is known about its significance in the general population. We studied the structure and function of the gastro-oesophageal junction in healthy volunteers with and without HH.

219. Comparative genomics of Crohn's disease-associated adherent-invasive Escherichia coli.

作者: Claire L O'Brien.;Marie-Agnès Bringer.;Kathryn E Holt.;David M Gordon.;Anaëlle L Dubois.;Nicolas Barnich.;Arlette Darfeuille-Michaud.;Paul Pavli.
来源: Gut. 2017年66卷8期1382-1389页
Adherent-invasive Escherichia coli (AIEC) are a leading candidate bacterial trigger for Crohn's disease (CD). The AIEC pathovar is defined by in vitro cell-line assays examining specific bacteria/cell interactions. No molecular marker exists for their identification. Our aim was to identify a molecular property common to the AIEC phenotype.

220. Cardiac mucosa, Barrett's oesophagus and cancer of the gastro-oesophageal junction: what's in a name?

作者: Stuart Jon Spechler.
来源: Gut. 2017年66卷8期1355-1357页
共有 16360 条符合本次的查询结果, 用时 1.7814556 秒